Maggie Segall Featured in Bloomberg Law’s “They’ve Got Next: 40 Under 40” Series
August 01, 2022
On July 28, 2022, Cravath partner Margaret T. Segall was featured in Bloomberg Law’s “They’ve Got Next: 40 Under 40” series, which recognizes “the accomplishments of stellar young lawyers nationwide,” based on their client work, leadership roles, pro bono service and more. In a Q&A, Maggie described her work leading antitrust strategy and global filing coordination for client AerCap in connection with its $30 billion acquisition of GE Capital Aviation Services, which along with her representation of Mylan in its $50 billion combination with Upjohn required securing clearances from competition authorities around the world. Maggie discussed the necessity for creative thinking in helping clients navigate challenging problems with little precedent, which happens often in today’s rapidly evolving regulatory environment. In a related article, Cravath partner Christine Varney, whom Maggie cites as a mentor, told Bloomberg Law that Maggie “has a remarkable, fine‑tuned ability to anticipate any concerns the government might raise and to devise creative solutions to avoid or neutralize objections.”
Related Practices & Industries
People
- Photo
-
-
J.D., 2008, Harvard Law Schoolcum laude
-
A.B., 2003, Harvard Collegemagna cum laude
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
March 10, 2021
AerCap’s Acquisition of GE Capital Aviation Services
On March 10, 2021, AerCap Holdings N.V. (“AerCap”), a global leader in aircraft leasing, announced that it has entered into a definitive agreement with General Electric (“GE”) under which AerCap will acquire 100% of GE Capital Aviation Services, a GE business. Under the terms of the agreement, which has been unanimously approved by the boards of directors of AerCap and GE, GE will receive 111.5 million newly issued AerCap shares, $24 billion of cash and $1 billion of AerCap notes and/or cash. Cravath is representing AerCap in connection with the transaction.
Deals & Cases
July 29, 2019
Mylan’s $50 Billion Combination with Upjohn, a Division of Pfizer
On July 29, 2019, Mylan N.V. and Pfizer Inc. announced a definitive agreement to combine Mylan with Upjohn, Pfizer's off-patent branded and generic established medicines business, creating a new global pharmaceutical company. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, each Mylan share would be converted into one share of the new company. Pfizer shareholders would own 57% of the combined new company, and Mylan shareholders would own 43%. Cravath is representing Mylan in connection with the transaction.
